Nicole Ballew Chang, Ph.D. is a Patent Agent in Lewis Roca Rothgerber Christie’s Intellectual Property practice group. Nicole draws on her doctorate in molecular and cellular biology, as well as experience working with startups, small businesses, and academia to provide critical insights to clients and the firm. She plays a key role in the firm’s biotech/pharmaceutical practice.
Clients turn to Nicole for assistance in U.S. and foreign patent prosecution in Biotechnology and Life Sciences – including pharmaceuticals, antibodies, molecular and cellular methodology, diagnostics, immunology, and small molecule chemistry. Her experience in academia and working with start-ups benefits clients throughout the patent application process.
- Lewis Roca Rothgerber Christie (legacy firm Christie Parker & Hale LLP), Patent Agent, 2009-present
- Ladas & Parry, LLP, Technical Specialist/Patent Agent, 2005-2008
- GlycoFi, Inc., Science Writer, 2003-2005
- Elsevier Science, Ltd., Chemistry & Biology Contract Writer, 2003-2004
- Dartmouth College, Genetics Teaching Assistant, Department of Biology, 1998
- Los Alamos National Laboratory, Life Sciences Graduate Research Assistant, 1994-1996
- Co-Author, "Optimization of Humanized IgGs in Glycoengineered Pichia pastoris," Nature Biotechnology, January 2006
- Co-Author, "A Rab Requirement Not Bypassed in SLY1-20 Suppression," Molecular Biology of the Cell, April 2005
- Author, "Revolutionizing protein production in fungi," Innovations in Pharmaceutical Technology, Biotechnology Section, June 2004
- Co-Author, “Production of therapeutic proteins in fungal hosts,”Expert Opinion on Biological Therapy, May 2004.
- Author, “Affinium Pharmaceuticals, Inc: Structure-Guided Drug Discovery” Chemistry & Biology, May 2004
- Author, Benitec, Ltd. “Gene Silencing from Down Under,” Chemistry & Biology, March 2004
- Author, “Tools for Nanoscience at McGill University, Sometimes Smaller is Better,” Chemistry & Biology, January, 2004.
- Author, “Cortex Pharmaceuticals, Inc., Maintaining Brain Function Goes a Long Way,” Chemistry & Biology, November 2003.
- Author, “ImmunoGen, Inc., Immunoconjugates in Cancer Therapy: If At First You Don't Succeed, Try, Try Again,” Chemistry & Biology, September 2003
- Co-Author, “Initial docking of ER-derived vesicles requires Uso1p and Ypt1p but is independent of SNARE proteins,” EMBO J. April, 1998